Bret Jensen

Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed among analysts. Click for my SANA update.

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed results for Descartes-08 in myasthenia gravis.

Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued profitability. Read more here.

Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong analyst support and funding until 2027.

Learn about the challenges facing the commercial real estate industry, from rising vacancy rates to bankruptcies like WeWork, in this article. Click for more.

Terns Pharmaceuticals' (TERN) stock has risen somewhat due to some optimism around its early-stage clinical programs particularly TERN-601. Read more here.

ANI Pharmaceuticals acquired Alimera Sciences, boosting its rare disease segment with a couple of durable ophthalmology products. See why ANIP stock is a Buy.

Kiniksa's revenues continue to increase at an impressive rate for its flagship drug Arcalyst and the company is moving toward profitability. Read more about this London-based biotech.

The market has endured significant volatility but ended Q3 near all-time highs, driven by investor optimism and the first Fed rate cut since 2020. Read more on what to expect in Q4.

Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity. Explore more details here.